U.S. Emerging Ovarian Cancer Therapeutics Market

U.S. Emerging Ovarian Cancer Therapeutics Market

 

RELEASE DATE
25-Jan-2002
REGION
North America
Research Code: A129-01-00-00-00
SKU: HC00814-NA-MR_04500
AvailableYesPDF Download

$2,450.00

Special Price $1,837.50 save 25 %

In stock
SKU
HC00814-NA-MR_04500

$2,450.00

$1,837.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This report gives detailed information about market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to disease stage, namely localized-, metastatic- and relapsed/refractory disease. Key market and technology trends are discussed relative to the future of the market.

Table of Contents

Overview

  • Scope And Segmentation
  • Epidemiology And Etiology
  • Clinical Staging
  • Symptoms and Diagnosis
  • Treatment and Survival
  • Market And Technology Trends

Market Dynamics

  • Challenges
  • Drivers
  • Restraints

Strategic Recommendations

  • Strategies Overview
  • Strategic Recommendations For Market Challenge 1
  • Strategic Recommendations For Market Challenge 2
  • Strategic Recommendations For Market Challenge 3
  • Strategic Recommendations For Market Challenge 4
  • Strategic Recommendations For Market Challenge 5

Frost And Sullivan Market Engineering Awards

  • Technology Innovation Award: Targeted Genetics Corporation
  • Strategic Alliance Innovation Award: Supergen Corporation
  • Technology Leadership Award: AltaRex Corporation
  • Merger And Acquisition Strategy Award: Alza Corporation
  • Business Development Strategy Award: MGI Pharma
This report gives detailed information about market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to disease stage, namely localized-, metastatic- and relapsed/refractory disease. Key market and technology trends are discussed relative to the future of the market.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number A129-01-00-00-00
Is Prebook No